Bracco Company Profile

What is the competitive landscape for BRACCO

BRACCO has forty-two approved drugs.

There are three US patents protecting BRACCO drugs.

There are forty-one patent family members on BRACCO drugs in thirteen countries and seventy-four supplementary protection certificates in eight countries.

Summary for Bracco

International Patents:	41
US Patents:	3
Tradenames:	65
Ingredients:	33
NDAs:	42

Drugs and US Patents for Bracco

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bracco	CARDIOGRAFIN	diatrizoate meglumine	INJECTABLE;INJECTION	011620-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Bracco	CHOLOVUE	iodoxamate meglumine	INJECTABLE;INJECTION	018077-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Bracco	IODOTOPE	sodium iodide i-131	SOLUTION;ORAL	010929-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Bracco	IOMERVU	iomeprol	SOLUTION;INTRAVENOUS	216017-005	Nov 27, 2024		RX	Yes	Yes
Bracco	IOMERVU	iomeprol	SOLUTION;INTRAVENOUS	216017-010	Nov 27, 2024		RX	Yes	Yes
Bracco	MULTIHANCE	gadobenate dimeglumine	INJECTABLE;INTRAVENOUS	021357-004	Nov 23, 2004		RX	Yes	Yes
Bracco	MULTIHANCE MULTIPACK	gadobenate dimeglumine	INJECTABLE;INTRAVENOUS	021358-002	Nov 23, 2004		RX	Yes	Yes

Expired US Patents for Bracco

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bracco	CHOLETEC	technetium tc-99m mebrofenin kit	INJECTABLE;INJECTION	018963-001	Jan 21, 1987	4,418,208
Bracco	CHOLOVUE	iodoxamate meglumine	INJECTABLE;INJECTION	018076-001	Approved Prior to Jan 1, 1982	3,654,272
Bracco	ISOVUE-370	iopamidol	INJECTABLE;INJECTION	018735-003	Dec 31, 1985	4,001,323
Bracco	ISOVUE-370	iopamidol	INJECTABLE;INJECTION	020327-004	Oct 12, 1994	4,001,323
Bracco	LUMASON	sulfur hexafluoride lipid-type a microspheres	FOR SUSPENSION;INTRAVENOUS	203684-001	Oct 15, 2014	5,686,060
Bracco	MULTIHANCE	gadobenate dimeglumine	INJECTABLE;INTRAVENOUS	021357-001	Nov 23, 2004	4,916,246
Bracco	MULTIHANCE MULTIPACK	gadobenate dimeglumine	INJECTABLE;INTRAVENOUS	021358-002	Nov 23, 2004	4,916,246

International Patents for Bracco Drugs

Country	Patent Number	Estimated Expiration
Australia	2020276679
Australia	2019298652
Japan	7357078
Singapore	11202111756U
South Korea	102742070
South Korea	20210029712
World Intellectual Property Organization (WIPO)	2020229643

Supplementary Protection Certificates for Bracco Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1912999	14C0076	France		PRODUCT NAME: SIMEPREVIR OU L'UN DE SES SELS, INCLUANT LE SEL DE SODIUM DE SIMEPREVIR; REGISTRATION NO/DATE: EU/1/14/924 20140516
2203431	1590018-6	Sweden		PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150119
2203431	2015/009	Ireland		PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REGISTRATION NO/DATE: EU/1/14/983 20150115
1856135	2020/017	Ireland		PRODUCT NAME: FOSTAMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, OR A HYDRATE, SOLVATE OR N-OXIDE OF FOSTAMATINIB OR THE PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, ESPECIALLY FOSTAMATINIB DISODIUM, OPTIONALLY IN FORM OF A HYDRATE; REGISTRATION NO/DATE: EU/1/19/1405 20200113
2563920	CA 2019 00001	Denmark		PRODUCT NAME: A COMPOUND COMPRISING A MODIFIED OLIGONUCLEOTIDE HAVING A NUCLEOBASE SEQUENCE CONSISTING OF 20 LINKED NUCLEOSIDES ACCORDING TO EP B1 2563920 CLAIM 1 (SEQ ID NO: 80), ...SPECIFICALLY INOTERSEN; AND ITS DERIVATIVES, INCLUDING SODIUM SALTS ...; REG. NO/DATE: EU/1/18/1296 20180710
1856135	LUC00153	Luxembourg		PRODUCT NAME: FOSTAMATINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE FOSTAMATINIB, OU UN HYDRATE, SOLVATE OU N-OXYDE DE FOSTAMATINIB OU LE SEL PHARMACEUTIQUEMENT ACCEPTABLE DE FOSTAMATINIB, EN PARTICULIER FOSTAMATINIB DISODIUM, EVENTUELLEMENT SOUS FORME D'HYDRATE; AUTHORISATION NUMBER AND DATE: EU/1/19/1405 20200113
2340828	LUC00195	Luxembourg		PRODUCT NAME: SACUBITRIL ET VALSARTAN, SOUS FORME DE COMPLEXE DE SEL DE SODIUM SACUBITRIL VALSARTAN, C'EST-A-DIRE (((S)-N-VALERYL-N-((2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL)-METHYL)-VALINE) ((2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-ESTER ETHYLIQUE D'ACIDE PENTANOIQUE))NA3 X H2O, DANS LEQUEL X EST 0 A 3; AUTHORISATION NUMBER AND DATE: EU/1/15/1058 20151123

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Bracco

Pharmaceutical Competitive Landscape Analysis: Bracco – Market Position, Strengths & Strategic Insights

The pharmaceutical industry is a dynamic and competitive arena, with companies vying for market share and innovation leadership. Among these players, Bracco Group stands out as a significant force in the healthcare sector, particularly in diagnostic imaging. This comprehensive analysis delves into Bracco's market position, strengths, and strategic insights, providing valuable information for industry professionals and investors alike.

Company Overview

Bracco Group, an Italian multinational, has established itself as a leader in the healthcare sector, with a strong focus on diagnostic imaging. Founded in 1927, the company has grown from a small pharmaceutical trading firm to a global enterprise with a presence in over 100 countries[1]. Bracco's core business revolves around the development, manufacture, and marketing of contrast agents and medical devices for various diagnostic imaging modalities.

Market Position

Global Reach and Revenue

Bracco's market position is characterized by its extensive global presence and substantial revenue. The company operates in over 90 markets worldwide, either directly or through subsidiaries, joint ventures, and distribution partnerships[2]. As of 2020, Bracco reported consolidated revenues of approximately 1.4 billion euros, with an impressive 89% of sales coming from international markets[1][4].

Product Portfolio

Bracco's strong market position is underpinned by its comprehensive product portfolio, which includes:

1. Contrast agents for X-ray imaging, CT, MRI, ultrasound, and nuclear medicine
2. Contrast-agent injection systems and advanced medical devices
3. Prescription and over-the-counter pharmaceuticals
4. Healthcare services through the CDI - Centro Diagnostico Italiano[1]

This diverse range of offerings allows Bracco to cater to various segments of the diagnostic imaging market, enhancing its competitive edge.

Strengths and Competitive Advantages

Innovation and R&D Focus

One of Bracco's key strengths lies in its commitment to innovation and research. The company invests approximately 10% of its core diagnostic imaging revenues in R&D activities[1]. This substantial investment has resulted in a portfolio of 1,800 patents, demonstrating Bracco's innovative prowess[1].

"Bracco continues to remain at the forefront of Imaging by investing in the development of solutions that enable our customers to tackle these challenges head on." - Vittorio Puppo, President and CEO, Bracco Diagnostics Inc.[3]

Global Manufacturing and R&D Network

Bracco's competitive advantage is further bolstered by its global network of manufacturing facilities and research centers. The company operates:

• Manufacturing facilities in Italy, Switzerland, Japan, China, and the United States
• Three integrated research centers in Italy, Switzerland, and the United States[2]

This global footprint enables Bracco to optimize production efficiency, maintain quality control, and foster innovation across different markets.

Strategic Collaborations and Acquisitions

Bracco has demonstrated a keen ability to forge strategic partnerships and make targeted acquisitions to enhance its market position. For instance:

1. In December 2021, Bracco entered into a worldwide strategic collaboration with Guerbet for the development of Gadopiclenol, a high-relaxivity contrast agent[4].
2. The acquisition of Squibb Diagnostic from Bristol Myers Squibb in 1994 significantly strengthened Bracco's presence in the U.S. market[1].

These strategic moves have allowed Bracco to expand its product offerings, enter new markets, and consolidate its position in the diagnostic imaging sector.

Market Trends and Opportunities

Growing Demand for Diagnostic Imaging

The global contrast media market is projected to grow at a CAGR of 5-6%, driven by advancements in imaging technology and increasing demand for accurate diagnostic tools[4]. This trend presents significant opportunities for Bracco to expand its market share and introduce innovative products.

Emerging Markets

The Asia Pacific region is anticipated to witness the highest CAGR in the radiopharmaceuticals market[8]. Bracco's established presence in markets like China positions it well to capitalize on this growth opportunity.

Personalized Medicine

The trend towards personalized medicine is creating new opportunities in the diagnostic imaging sector. Bracco's ISOVUE® Imaging Bulk Package, which allows for custom-tailored contrast media dosing, aligns well with this trend[3].

Challenges and Competition

Regulatory Environment

The pharmaceutical industry, including the diagnostic imaging sector, is subject to stringent regulatory requirements. Bracco must navigate these regulations across multiple jurisdictions, which can impact product development timelines and market entry strategies.

Intense Competition

Bracco faces competition from other major players in the diagnostic imaging market, including Novartis AG, Lantheus Holdings, Inc., GE HealthCare, and Bayer AG[8]. These companies also invest heavily in R&D and pursue aggressive growth strategies, intensifying the competitive landscape.

Market Consolidation

The radiopharmaceuticals market reflects a semi-consolidated structure[8]. This trend towards consolidation could pose challenges for Bracco in maintaining its market share and may necessitate further strategic partnerships or acquisitions.

Strategic Insights

Focus on High-Growth Markets

Bracco should continue to prioritize expansion in high-growth markets, particularly in the Asia Pacific region. This could involve strengthening local partnerships, investing in regional R&D capabilities, and tailoring products to meet specific market needs.

Embrace Digital Transformation

Investing in digital technologies and data analytics could help Bracco enhance its product offerings, improve operational efficiency, and provide value-added services to healthcare providers.

Sustainability Initiatives

As environmental, social, and governance (ESG) factors become increasingly important to stakeholders, Bracco should consider strengthening its sustainability initiatives. The company's recent joining of the UN Global Compact is a step in this direction[7].

Future Outlook

Bracco's strong market position, innovative product portfolio, and global presence position it well for future growth in the diagnostic imaging sector. However, the company will need to navigate challenges such as intense competition and evolving regulatory landscapes.

By continuing to invest in R&D, pursuing strategic partnerships, and capitalizing on emerging market opportunities, Bracco can maintain and potentially enhance its competitive edge in the pharmaceutical industry.

Key Takeaways

1. Bracco Group is a leading player in the diagnostic imaging sector, with a global presence and diverse product portfolio.
2. The company's strengths include a strong focus on innovation, a global manufacturing and R&D network, and strategic collaborations.
3. Market trends such as growing demand for diagnostic imaging and personalized medicine present significant opportunities for Bracco.
4. Challenges include navigating regulatory environments, intense competition, and market consolidation.
5. Future success will depend on Bracco's ability to capitalize on high-growth markets, embrace digital transformation, and address sustainability concerns.

FAQs

1. What is Bracco Group's primary focus in the pharmaceutical industry? Bracco Group primarily focuses on diagnostic imaging, developing and manufacturing contrast agents, medical devices, and advanced solutions for various imaging modalities.

2. How does Bracco maintain its competitive edge in the market? Bracco maintains its competitive edge through substantial investments in R&D, a global manufacturing and research network, strategic collaborations, and a diverse product portfolio.

3. What are the key growth opportunities for Bracco in the coming years? Key growth opportunities include expanding in emerging markets, particularly in Asia Pacific, capitalizing on the trend towards personalized medicine, and leveraging advancements in imaging technology.

4. How does Bracco's market position compare to its competitors? Bracco is among the leading players in the diagnostic imaging market, competing with companies like Novartis AG, Lantheus Holdings, Inc., and GE HealthCare. Its strong global presence and innovative product portfolio contribute to its competitive position.

5. What strategies could Bracco employ to address future challenges in the industry? To address future challenges, Bracco could focus on expanding in high-growth markets, investing in digital transformation, strengthening sustainability initiatives, and continuing to pursue strategic partnerships and acquisitions.

Sources cited:

1. https://en.wikipedia.org/wiki/Bracco_(company)
2. https://www.bracco.com/en-us/bracco-glance
3. https://www.biospace.com/bracco-diagnostics-inc-creates-first-and-only-u-s-fda-approved-multi-dose-compliant-contrast-medium-as-breakthrough-solution-for-point-of-care-use-i
4. https://meditechinsights.com/contrast-media-market/
5. https://www.researchandmarkets.com/reports/1957437/bracco_spa_strategic_swot_analysis_review
6. https://www.fortunebusinessinsights.com/industry-reports/nuclear-medicine-radiopharmaceuticals-market-101812